Aurinia Pharmaceuticals Inc.
A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.
Bought 814.6K
Bought 5.00M
Granted 1.68M · Sold 529.6K
Granted 827.0K · Bought 10.0K · Sold 168.6K
Granted 612.4K · Sold 199.9K
Granted 507.1K · Sold 167.3K
Granted 365.7K · Bought 5.0K · Sold 51.9K
Granted 191.5K · Sold 30.1K
Granted 464.7K · Bought 30.0K · Sold 482.3K
Granted 103.2K · Sold 40.5K
Granted 116.1K
Granted 116.1K
Granted 403.5K · Sold 449.8K
Granted 8.7K · Bought 25.0K
Granted 130.6K · Sold 204.8K
Granted 40.2K · Sold 13.7K
Granted 18.0K · Sold 9.9K
Granted 30.2K · Bought 1.6K · Sold 10.4K
Granted 30.0K · Sold 5.2K
Granted 30.0K · Sold 4.6K
Granted 18.0K · Bought 5.0K · Sold 10.4K
Granted 18.0K · Sold 520
Granted 20.6K
Granted 8.5K · Sold 3.2K
Granted 48.7K · Sold 40.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tang Capital Management LLC +1 co-filer10% owner, Chief Executive Officer, Director, 10% owner · 5 transactions | — | 13.04M | — | 814.6K | — |
| Tang KevinDirector · 18 transactions | — | 12.23M | — | 5.00M | — |
| Greenleaf PeterChief Executive Officer, Director · 14 transactions | +13580.1% | 1.84M | 1.68M | — | 529.6K |
| Donley Matthew MaxwellChief Operating Officer · 15 transactions | +6771.7% | 680.3K | 827.0K | 10.0K | 168.6K |
| Robertson Stephen P.Chief Legal Officer · 14 transactions | +22745.7% | 621.4K | 612.4K | — | 199.9K |
| Miller Joseph MChief Financial Officer · 14 transactions | +57542.1% | 576.4K | 507.1K | — | 167.3K |
| Habig Scott MichaelChief Commercial Officer · 6 transactions | — | 456.3Kas of Aug 2024 | 365.7K | 5.0K | 51.9K |
| Knappertz VolkerEVP, Research and Development · 3 transactions | — | 319.1Kas of Feb 2024 | 191.5K | — | 30.1K |
| Martin Michael RobertChief Business Officer · 28 transactions | +40.6% | 259.2Kas of Mar 2023 | 464.7K | 30.0K | 482.3K |
| Keenan GregSVP, Chief Medical Officer · 7 transactions | — | 154.4K | 103.2K | — | 40.5K |
| Cole RyanChief Operating Officer · 1 transaction | — | 116.1K | 116.1K | — | — |
| Hearne Michael SChief Financial Officer · 1 transaction | — | 116.1K | 116.1K | — | — |
| Solomons NeilChief Medical Officer · 13 transactions | -30.2% | 95.8Kas of Mar 2022 | 403.5K | — | 449.8K |
| Milne George M JrDirector · 3 transactions | +75% | 78.7Kas of May 2023 | 8.7K | 25.0K | — |
| Huizinga Robert BindertEVP of Research · 12 transactions | -48.3% | 74.2Kas of Mar 2022 | 130.6K | — | 204.8K |
| Jayne David R.W.Director · 6 transactions | +88.3% | 56.5Kas of Nov 2024 | 40.2K | — | 13.7K |
| Billen DanielDirector · 4 transactions | +40.7% | 28.1Kas of May 2024 | 18.0K | — | 9.9K |
| Leversage JillDirector · 6 transactions | +577.1% | 25.1Kas of Nov 2024 | 30.2K | 1.6K | 10.4K |
| Smith Karen L.Director · 3 transactions | — | 24.8Kas of Nov 2024 | 30.0K | — | 5.2K |
| Bailey Jeffrey AllenDirector · 4 transactions | — | 22.8K | 30.0K | — | 4.6K |
| MacKay-Dunn R. HectorDirector · 5 transactions | +322.6% | 18.6Kas of May 2024 | 18.0K | 5.0K | 10.4K |
| Balakrishnan BrindaDirector · 3 transactions | — | 17.5Kas of May 2024 | 18.0K | — | 520 |
| Johnson Craig ADirector · 2 transactions | — | 14.6K | 20.6K | — | — |
| Colao MassimilanoChief Commercial Officer · 2 transactions | +64.6% | 13.5Kas of Mar 2022 | 8.5K | — | 3.2K |
| Hagan Joseph PDirector · 5 transactions | +241.7% | 12.0Kas of May 2023 | 48.7K | — | 40.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +3.47M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.